---
schema_version: "secwatch.filing_event.v1"
accession: "0001070081-26-000006"
form_type: "8-K"
ticker: "PTCT"
cik: "0001070081"
company_name: "PTC THERAPEUTICS, INC."
filed_at: "2026-04-28T23:59:59+00:00"
generated_at: "2026-05-15T02:41:29.350106+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# PTC Therapeutics reports positive PIVOT-HD extension data: 52% slowing of HD progression at 10 mg votoplam

## Summary
- Stage 2 HD participants showed 52% (10 mg) and 28% (5 mg) slowing on cUHDRS vs natural history at 24 months.
- Mean NfL levels remained below baseline at 24 months for both doses, contrasting with natural history increases.
- Safety data at Month 24 consistent with prior favorable safety profile; no treatment-related NfL increases.
- Novartis has initiated global Phase 3 INVEST-HD study of votoplam (10 mg vs placebo, n≈770, primary endpoint cUHDRS at 36 months).

## SEC filing metadata
- accession: 0001070081-26-000006
- form_type: 8-K
- ticker: PTCT
- cik: 0001070081
- company_name: PTC THERAPEUTICS, INC.
- filed_at: 2026-04-28T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1070081/000107008126000006/0001070081-26-000006-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1070081/000107008126000006/tmb-20260428x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001070081-26-000006
- JSON: https://secwatch.observer/filing/0001070081-26-000006.json
- Plain text: https://secwatch.observer/filing/0001070081-26-000006.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.